Allogeneic stem cell transplantation is allowed provided the patient is >= 1 year from transplant at time of registration, is not on immunosuppressive therapy to treat/prevent graft-versus-host disease, has no evidence of active graft versus host disease, and no evidence of active infection
At least 3 months from allogeneic stem cell transplantation and off immunosuppression and no evidence of graft versus host disease (GVHD)
Prior allogeneic stem cell transplantation with active graft-versus-host-disease.
Patients with a history of allogeneic stem cell transplantation are eligible for study participation provided the transplant was > 100 days prior to the first dose of treatment on study; patients must be off of immunosuppressive therapies for at least 4 weeks prior to the first dose of treatment on study without signs or symptoms of graft versus host disease other than grade 1 skin involvement
Patients who have undergone stem cell transplantation (SCT), autologous or allogeneic, are eligible provided that they are >= 8 weeks from stem cell infusion, have no active graft versus host disease (GVHD), are off immune suppression for at least 2 weeks, and do not have a history of veno-occlusive disease (VOD)
Patients with history of allogeneic stem cell transplantation are eligible if at least 100 days post-transplant, if there is no evidence of active graft versus host disease (GVHD) and no longer taking immunosuppressive agents for at least 30 days prior to enrollment
Prior allogeneic stem cell transplantation (SCT) is an exclusion only if the subject has active graft vs host disease or requires immunosuppression other than a constant stable dose of glucocorticoids (the latter is permitted)
Prior allogeneic stem cell transplantation with active graft-versus-host- disease
High risk prediction score as determined by the Mount Sinai Acute Graft Versus Host Disease (GVHD) International Consortium (MAGIC) algorithm at either day 7 or day 14 post hematopoietic stem cell transplantation (HCT).
Patients with history of allogeneic stem cell transplantation are eligible if at least 100 days post-transplant, if there is no evidence of active GVHD and no longer taking immunosuppressive agents for at least 30 days prior to enrollment
In subjects with prior hematopoietic progenitor cell transplantation, evidence of ongoing graft-versus-host disease (GVHD).
AML relapse > 6 months since autologous or allogeneic stem cell transplantation, provided there is no active graft-versus-host disease (GVHD) > grade 1; no treatment with high dose steroids for GVHD (up to 20 mg prednisolone or equivalent); no treatment with immunosuppressive drugs with the exception of low dose cyclosporine and tacrolimus (blood levels of 0.5-0.6 ug/mL)
Meets one of the following disease criteria:\r\n* Multiple myeloma (MM) meeting one of the following:\r\n** Relapsed/refractory disease after two lines of therapies, including a proteasome inhibitor (bortezomib, carfilzomib or ixazomib) and an immunomodulatory drug (thalidomide, lenalidomide or pomalidomide)\r\n** Relapsed disease between 2-18 months of 1st autologous stem cell transplantation\r\n** Relapsed disease at least 4 months after allogeneic stem cell transplantation with no evidence of active graft versus host disease AND with measurable disease defined as serum IgG, A, M M-protein >= 0.5 g/dL or serum IgD M-protein >= 0.5 g/dL, or urine M-protein >= 200 mg/24 hours AND at least at least 4 weeks since plasmapheresis\r\n* CD20-positive B-cell non-Hodgkin lymphoma (NHL)\r\n** CD20 expression confirmed by flow cytometry or immunohistochemistry and meeting one or more of the following:\r\n** Evidence of relapsed/refractory disease that has failed conventional therapy\r\n** Relapsed disease at least 60 days after autologous stem cell transplantation\r\n** Relapsed disease at least 4 months after allogeneic stem cell transplantation with no evidence of active graft versus host disease\r\n** Has measurable disease > 1.5 cm in diameter
Patients with prior autologous or allogeneic hematopoietic cell transplantation (HCT) are eligible if relapse occurs provided symptoms of graft-versus host disease are well controlled with stable use of immunosuppressive agents
Patients who have had prior SCT are eligible if they have a relapse > 3 months since autologous or allogeneic stem cell transplantation provided, 1) no clinically significant active graft-versus-host disease (GVHD > grade 1); 2) no treatment with high dose steroids for GVHD (i.e. > 20 mg prednisolone or equivalent per day); 3) no treatment with immunosuppressive drugs with the exception of cyclosporine and tacrolimus
Patient participants who have undergone allogeneic SCT (alloSCT) are eligible if they are >= 60 days from stem cell infusion, have no evidence of graft versus host disease (GVHD) > grade 1, and are >= 2 weeks off all immunosuppressive therapy
Chronic graft-versus-host disease requiring systemic immunosuppression post-allogeneic hematopoietic stem cell transplantation
Patients who have undergone stem cell transplantation (SCT), autologous or allogeneic, are eligible provided that they are > 60 days from stem cell infusion, have graft-versus-host disease (GVHD) =< grade 1 and are off immunosuppressive agents for > 28 days at time of registration
Patient must meet one of the following criteria: \r\n* Patient refractory to one or two standard induction regimen \r\n* Patients with a first untreated relapse within 2 years of documentation of clinical remission; patients relapsing after allogeneic stem cell transplantation are eligible if more than 12 months after transplantation and without sign of active graft versus host disease (GVHD)
Patients with prior autologous and allogeneic hematopoietic stem cell transplantation are eligible if patients are off immunosuppression for greater than 14 days and have no evidence of active graft versus host disease (GVHD) except grade 1 skin GVHD
Prior allogeneic transplants is allowed prior to study start (1st dose of study medication), but patients must also be at least 6 months from date of stem cell infusion, have no evidence of graft versus host disease (GVHD), be off all immunosuppressant medications, and have recovered to =< grade 1 toxicities related to this procedure
Relapse > 6 months since autologous or allogeneic stem cell transplantation provided:\r\n* No active graft-versus-host disease (GVHD > grade 1)\r\n* No treatment with high dose steroids for GVHD (up to >= 20 mg prednisolone or equivalent per day)\r\n* No treatment with immunosuppressive drugs with the exception of low dose cyclosporine and tacrolimus
Patients with relapsed or primary refractory AML; patients with relapsed AML after allogeneic stem cell transplantation, including those who have received donor lymphocyte infusions, are eligible if they have no active graft versus host disease (GVHD) and are off immunosuppression
Patients having undergone prior allogeneic stem cell transplantation within 6 months or having active graft versus host disease.
Previous allogeneic stem cell transplantation with active graft versus host disease (GVHD), or treatment with immunosuppressive therapy (excluding corticosteroids) in the 2 months prior to study entry
Patients who have undergone allogeneic SCT (alloSCT) are eligible if they are >= 60 days post stem cell infusion, have no evidence of graft-versus-host disease (GVHD) > grade 1, and are >= 2 weeks off all immunosuppressive therapy
Patients with history of allogeneic stem cell transplantation are eligible if at least 100 days post-transplant, if there is no evidence of active graft-versus-host disease (GVHD) and no longer taking immunosuppressive agents for at least 30 days prior to enrollment
Prior hematopoietic stem cell transplantation within 12 weeks of the first dose of study treatment or ongoing immunosuppressive therapy for graft versus host disease
Patients who have received allogeneic hematopoietic stem cell transplantation will be eligible 6 months after the procedure provided there is no evidence of active graft-versus-host disease and immunosuppressive treatment has been discontinued for at least 30 days.
Patients with allogeneic stem cell transplantation within the last 6 months or patients with active graft-versus-host disease (GVHD) will be excluded
For patients with relapsed/refractory disease: patients with prior autologous or allogeneic hematopoietic cell transplantation (HCT) for MDS/AML are eligible if relapse occurs provided symptoms of graft-versus host disease are well controlled with stable use of immunosuppressive agents
Active graft versus host disease (GVHD) after allogeneic stem cell transplantation; at least 2 months must have elapsed since completion of an allogeneic stem cell transplantation
Patients who have received allogenic stem cell transplantation < 12 months prior to entering the study or show evidence of active graft-versus-host disease that requires immunosuppressive therapy
Patients who have undergone stem cell transplantation (SCT), autologous or allogeneic, are eligible provided that they are > 84 days from stem cell infusion, have no active graft-versus-host disease (GVHD), are off immunosuppressive agents for > 14 days
Participants who have had prior allogeneic stem cell transplantation with evidence of active graft-versus-host disease requiring immunosuppressive therapy
Recipients of prior allogeneic hematopoietic stem cell transplantation for AML or acute leukemia of ambiguous lineage are eligible if they do not have graft-versus-host disease (GVHD) or they have quiescent GVHD whether or not they are receiving immunosuppressive therapy
Patients must have no evidence of active graft-versus-host disease and must be on a stable immunosuppressive regimen (or no immunosuppressive medications) without a change in drugs dosage in the 4 weeks prior to the planned CD8+ memory T cell infusion
Patients who have undergone prior stem cell transplantation will not be excluded from study entry; at least 3 months must have elapsed since autologous or allogeneic stem cell transplantation; patients must have no evidence of active graft versus host disease
Patients with prior autologous and allogeneic hematopoietic stem cell transplantation are eligible if patients are off immunosuppression for > 1 month and have no evidence of active graft versus host disease (GVHD) except grade 1 skin GVHD
Any evidence of ongoing graft-versus-host disease (GVHD) in subjects with prior progenitor cell transplantation;
Patients following allogeneic stem cell transplantation are eligible in the absence of graft versus host disease and are off immunosuppression for at least 30 days
Allogeneic stem cell transplantation within the last 28 days before first treatment with graft versus host disease requiring more than 20 mg of steroids per day. Steroid dosage must be stable within two weeks prior to start of treatment.
AML relapse > 6 months since autologous or allogeneic stem cell transplantation, provided they are in first or second relapse and: No active graft-versus-host disease (GVHD > grade 1). No treatment with high dose steroids for GVHD (up to 20 mg Prednisolone or equivalent, Appendix G). No treatment with immunosuppressive drugs with the exception of low dose cyclosporine and tacrolimus (blood levels of 0.5-0.6 µg/mL).
Patients with prior autologous or allogeneic hematopoietic cell transplantation (HCT) are eligible if relapse occurs provided symptoms of graft-versus host disease are well controlled with stable use of immunosuppressive agents
Patients who have had prior allogeneic stem cell transplantation and show evidence of active graft-versus-host disease that requires immunosuppressive therapy
Patients with active graft versus host disease after allogeneic stem cell transplantation. At least 3 months must have elapsed since completion of allogeneic stem cell transplantation except for patients with AML, where at least 2 months must have elapsed;
Active graft versus host disease (after allogeneic stem cell transplantation) at C1D1.
Adult HCT survivors as defined by being at least 100 days post autologous or allogeneic transplantation for a malignant disease; all hematologic malignancies will be included; there is no restriction to enrollment by donor type, donor cell source, presence or absence of graft versus host disease
Active graft versus host disease (after allogeneic stem cell transplantation) at C1D1.
Patients who have undergone prior allogeneic transplantation are eligible provided they do not have significant active graft versus host disease and that their transplant day 0 is > 6 months from their first dose of chemotherapy
Prior allogeneic hematopoietic cell transplantation (HCT) with active graft versus host disease (GVHD) on therapeutic dosing of immunosuppression or prednisone > 20 mg daily equivalent
Patients with a history of allogeneic hematopoietic stem cell transplantation (HSCT) will be eligible if they are more than 90 days removed from the date of stem cell infusion, have no evidence of acute graft-versus-host disease (GVHD) or active chronic (grade 2-4) GVHD, and are off of all transplant-related immunosuppression for at least 2 weeks
